Cargando…

Longitudinal hearing loss in Wolfram syndrome

BACKGROUND: Wolfram syndrome (WFS) is a rare autosomal recessive disease with clinical manifestations of diabetes mellitus (DM), diabetes insipidus (DI), optic nerve atrophy (OA) and sensorineural hearing loss (SNHL). Although SNHL is a key symptom of WFS, there is limited information on its natural...

Descripción completa

Detalles Bibliográficos
Autores principales: Karzon, Roanne, Narayanan, Anagha, Chen, Ling, Lieu, Judith E. C., Hershey, Tamara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020390/
https://www.ncbi.nlm.nih.gov/pubmed/29945639
http://dx.doi.org/10.1186/s13023-018-0852-0
_version_ 1783335287429005312
author Karzon, Roanne
Narayanan, Anagha
Chen, Ling
Lieu, Judith E. C.
Hershey, Tamara
author_facet Karzon, Roanne
Narayanan, Anagha
Chen, Ling
Lieu, Judith E. C.
Hershey, Tamara
author_sort Karzon, Roanne
collection PubMed
description BACKGROUND: Wolfram syndrome (WFS) is a rare autosomal recessive disease with clinical manifestations of diabetes mellitus (DM), diabetes insipidus (DI), optic nerve atrophy (OA) and sensorineural hearing loss (SNHL). Although SNHL is a key symptom of WFS, there is limited information on its natural history using standardized measures. Such information is important for clinical care and determining its use as an outcome measure in clinical trials. METHODS: Standardized audiologic measures, including pure-tone testing, tympanometry, speech perception, and the unaided Speech Intelligibility Index (SII) were assessed in patients with confirmed WFS annually. Mixed model analyses were used to examine main effects of age, time or interactions for pure tone average (PTA), high frequency average (HFA) and SII. RESULTS: Forty WFS patients were evaluated between 1 and 6 times. Mean age at initial enrollment was 13.5 years (SD = 5.6). Patients were classified as having normal hearing (n = 10), mild-to-severe (n = 24) or profound SNHL (n = 6). Mean age of diagnosis for SNHL was 8.3 years (SD = 5.1) with 75% prevalence. HFA worsened over time for both ears, and SII worsened over time in the worse ear, with greater decline in both measures in younger patients. Average estimated change over 1 year for all measures was in the subclinical range and power analyses suggest that 100 patients would be needed per group (treatment vs. placebo) to detect a 60% reduction in annual change of HFA over 3 years. If trials focused on just those patients with SNHL, power estimates suggest 55 patients per group would be sufficient. CONCLUSIONS: Most patients had a slow progressive SNHL emerging in late childhood. Change over time with standard audiologic tests (HFA, SII) was small and would not be detectable for at least 2 years in an individual. Relatively large sample sizes would be necessary to detect significant impact on hearing progression in a clinical trial. Hearing function should be monitored clinically in WFS to provide appropriate intervention. Because SNHL can occur very early in WFS, audiologists and otolaryngologists should be aware of and refer for later emerging symptoms. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-018-0852-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6020390
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60203902018-07-06 Longitudinal hearing loss in Wolfram syndrome Karzon, Roanne Narayanan, Anagha Chen, Ling Lieu, Judith E. C. Hershey, Tamara Orphanet J Rare Dis Research BACKGROUND: Wolfram syndrome (WFS) is a rare autosomal recessive disease with clinical manifestations of diabetes mellitus (DM), diabetes insipidus (DI), optic nerve atrophy (OA) and sensorineural hearing loss (SNHL). Although SNHL is a key symptom of WFS, there is limited information on its natural history using standardized measures. Such information is important for clinical care and determining its use as an outcome measure in clinical trials. METHODS: Standardized audiologic measures, including pure-tone testing, tympanometry, speech perception, and the unaided Speech Intelligibility Index (SII) were assessed in patients with confirmed WFS annually. Mixed model analyses were used to examine main effects of age, time or interactions for pure tone average (PTA), high frequency average (HFA) and SII. RESULTS: Forty WFS patients were evaluated between 1 and 6 times. Mean age at initial enrollment was 13.5 years (SD = 5.6). Patients were classified as having normal hearing (n = 10), mild-to-severe (n = 24) or profound SNHL (n = 6). Mean age of diagnosis for SNHL was 8.3 years (SD = 5.1) with 75% prevalence. HFA worsened over time for both ears, and SII worsened over time in the worse ear, with greater decline in both measures in younger patients. Average estimated change over 1 year for all measures was in the subclinical range and power analyses suggest that 100 patients would be needed per group (treatment vs. placebo) to detect a 60% reduction in annual change of HFA over 3 years. If trials focused on just those patients with SNHL, power estimates suggest 55 patients per group would be sufficient. CONCLUSIONS: Most patients had a slow progressive SNHL emerging in late childhood. Change over time with standard audiologic tests (HFA, SII) was small and would not be detectable for at least 2 years in an individual. Relatively large sample sizes would be necessary to detect significant impact on hearing progression in a clinical trial. Hearing function should be monitored clinically in WFS to provide appropriate intervention. Because SNHL can occur very early in WFS, audiologists and otolaryngologists should be aware of and refer for later emerging symptoms. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13023-018-0852-0) contains supplementary material, which is available to authorized users. BioMed Central 2018-06-27 /pmc/articles/PMC6020390/ /pubmed/29945639 http://dx.doi.org/10.1186/s13023-018-0852-0 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Karzon, Roanne
Narayanan, Anagha
Chen, Ling
Lieu, Judith E. C.
Hershey, Tamara
Longitudinal hearing loss in Wolfram syndrome
title Longitudinal hearing loss in Wolfram syndrome
title_full Longitudinal hearing loss in Wolfram syndrome
title_fullStr Longitudinal hearing loss in Wolfram syndrome
title_full_unstemmed Longitudinal hearing loss in Wolfram syndrome
title_short Longitudinal hearing loss in Wolfram syndrome
title_sort longitudinal hearing loss in wolfram syndrome
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020390/
https://www.ncbi.nlm.nih.gov/pubmed/29945639
http://dx.doi.org/10.1186/s13023-018-0852-0
work_keys_str_mv AT karzonroanne longitudinalhearinglossinwolframsyndrome
AT narayanananagha longitudinalhearinglossinwolframsyndrome
AT chenling longitudinalhearinglossinwolframsyndrome
AT lieujudithec longitudinalhearinglossinwolframsyndrome
AT hersheytamara longitudinalhearinglossinwolframsyndrome